AGTC-501 Gene Therapy Offers Vision Gains for X-Linked RP
AGTC-501 (Applied Genetic Technologies Corporation), a novel gene therapy in development for the potential treatment of X-linked retinitis pigmentosa (RP), showed an acceptable safety profile and visual function improvements when administered in the study’s higher dose groups, according to Robert A. Sisk, MD, FACS, from the Cincinnati Eye Institute in Ohio.
Applied Genetic Technologies exceeds enrollment target for SKYLINE trial of AGTC-501
Applied Genetic Technologies Corp. announced it had exceeded the enrollment target in the Company’s SKYLINE trial of AGTC-501, a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa (XLRP).
AGTC: The New Leader in Ocular Gene Therapy With Sue Washer
Sue Washer, president and CEO of Applied Genetic Technologies Corporation (AGTC), discusses ocular gene therapy with the Eye Care Insider podcast host Joshua Mali, MD.
AGTC Is Excited To Announce Seasoned Healthcare Financial and Operations Executive Jonathan I. Lieber As Their New Chief Financial Officer
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, announced Jonathan I. Lieber as their new Chief Financial Officer.
Greater Gift, AGTC, and 2020 On-Site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
Greater Gift of Winston Salem, a non-profit that celebrates participation in clinical trials, announced a partnership with UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company developing genetic therapies for the treatment of rare inherited retinal diseases (IRDs), and mobile vision provider 2020 On-site, a company involved in IRD clinical research and provides complimentary eye exams and facilitates the delivery of eyeglasses to students in need.
AGTC Announces Sponsorship of Achroma Corp’s No Roadblocks Program
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, announced it will be a sponsor of the Achroma Corp program, No Roadblocks.
AGTC Reports 12-Month Data From Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients With Mutations in the ACHM
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, reported 12-month data from its ongoing achromatopsia (ACHM) Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.
Gene Therapy Manufacturer Expands Its Footprint in Alachua County
AGTC, a UF startup and UF Innovate | Sid Martin Biotech alum, is determined to change the rare diseases narrative.
AGTC Breaks Ground on New Biotech Lab in Alachua
Applied Genetic Technologies Corporation will build a new 21,000 square foot laboratory facility in Alachua. The facility will include control labs and a manufacturing suite and will add 50 jobs.
AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has initiated plans to lease a build-to-suit 21,000 square foot current Good Manufacturing Practices (cGMP) manufacturing and quality control facility adjacent to its Florida facility to prepare for anticipated late-stage development of its X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia (ACHM) programs.
